NEW YORK, December 6, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Intuitive Surgical, Inc. (NASDAQ: ISRG), Medivation Inc. (NASDAQ: MDVN), and Impax Laboratories Inc. (NASDAQ: IPXL). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Johnson & Johnson Research Report
On December 3, 2013, Janssen Research & Development, LLC (Janssen), part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Johnson & Johnson), announced that new data involving its novel oral anticoagulant XARELTO (rivaroxaban) is scheduled to be presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, Los Angeles, from December 7, 2013 to December 10, 2013. Janssen reported that notable presentations include Statin Use Was Associated With a Non-Significant Reduction In The Observed Incidence Of Recurrent VTE In Einstein-DVT and Einstein-PE, which will take place on December 7, 2013, 5:30 p.m. to 7:30 p.m. CST, at Hall E (Ernest N. Morial Convention Center); Performance Of The Simplified PESI Score In Patients With Pulmonary Embolism Treated With Rivaroxaban Or Standard Therapy, which will also take place on December 7, 2013, 5:30 p.m. to 7:30 p.m. CST, at Hall E (Ernest N. Morial Convention Center); and A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For FXa Inhibitors, to be presented on December 9, 2013 6:00 p.m. to 8:00 p.m. CST. at Hall E (Ernest N. Morial Convention Center). The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Alexion Pharmaceuticals, Inc. Research Report
On December 3, 2013, Alexion Pharmaceuticals, Inc.'s (Alexion) stock declined 1.32%, ending the day at $122.16. Over the previous three trading sessions, shares of Alexion gained 0.76% compared to the Nasdaq Composite which declined 0.19% during the same period. The Full Research Report on Alexion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Intuitive Surgical, Inc. Research Report
On December 3, 2013, Intuitive Surgical, Inc.'s (Intuitive Surgical) stock declined 0.71%, ending the day at $372.81. Over the previous three trading sessions, shares of Intuitive Surgical declined 1.38% compared to the Nasdaq Composite which declined 0.19% during the same period. The Full Research Report on Intuitive Surgical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Medivation Inc. Research Report
On December 3, 2013, Medivation, Inc. (Medivation) and Astellas Pharma Inc. (Astellas) announced enrollment of the first patient in a global Phase 3 clinical trial, PROSPER, which will evaluate the safety and efficacy of enzalutamide in patients with non-metastatic (often referred to as M0) castration-resistant prostate cancer (CRPC). According to the Company, no prescription medicine is specifically approved for the treatment of patients with non-metastatic CRPC in the US. David Hung, M.D., President and CEO of Medivation, said, "PROSPER targets an important patient population as we and Astellas look to advance the development of enzalutamide further upstream in the prostate cancer treatment paradigm. The initiation of this trial underscores our commitment to develop enzalutamide as a potential treatment for those touched by this disease." The Full Research Report on Medivation Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Impax Laboratories Inc. Research Report
On December 3, 2013, Impax Laboratories Inc. (Impax) announced that the Company has entered into an agreement with Purdue Pharma L.P. to settle all outstanding patent litigation related to Impax's generic version of the currently marketed, reformulated OxyContin. Impax reported that it will have the right to market a specified number of bottles of its generic OxyContin, contingent upon the Company receiving final approval from the US Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for generic OxyContin or to launch a specified number of bottles of an authorized generic version of OxyContin if Impax does not have final ANDA approval, in each case starting January 1, 2016 under the terms of the agreement. The Full Research Report on Impax Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner